Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video

Genetic counseling and testing (GCT) provides invaluable information for women who are at-risk of hereditary breast and/or ovarian cancer (HBOC). Black women underutilize GCT compared to White women. This study will conduct a RCT to test the efficacy of a culturally-tailored theory-based video intervention aimed to address key psychosocial factors …

  • 0 views
  • 08 Dec, 2021
  • 1 location
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, …

triple negative breast cancer
progesterone
estrogen
HER2
erbb2
  • 0 views
  • 16 Mar, 2022
  • 8 locations
Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

The efficacy and safety of immunotherapy and antiangiotherapy in combination with chemotherapy in neoadjuvant therapy for triple-negative breast cancer (TNBC) were determined by the addition of sintilimab and apatinib to neoadjuvant chemotherapy To clarify the breast-conserving rate, toxicity, difference in pathologic complete response (pCR) rate of patients with PD-L1 (+) …

estrogen receptor
progesterone
EGFR
estrogen
growth factor
  • 0 views
  • 09 May, 2022
  • 1 location
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC (GASTHER2)

BACKGROUND: Gastric cancer is one of the most common cancers and is one of the most deadly cancers. Most patients have advanced disease and should receive first-line trastuzumab-associated chemotherapy when the biopsy is positive for immunocytochemical expression and / or HER2 gene amplification. A study conducted by our group noted …

  • 0 views
  • 30 May, 2022
  • 1 location
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy

use of modern chemotherapy regimens and targeted therapies, especially in patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer and triple negative breast cancer (TNBC

  • 0 views
  • 25 Aug, 2021
  • 1 location
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.

immunohistochemistry
growth factor
her1
breast cancer
epidermal growth factor
  • 0 views
  • 05 Mar, 2022
  • 1 location
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE)

Systematic assessment of survival data of patients who have been tested with EndoPredict; prospective proof that patients with low risk classification by EndoPredict (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.

  • 3 views
  • 12 Feb, 2022
  • 44 locations
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC)

EGFR
locally advanced breast cancer
aromatase inhibitor
palbociclib
epidermal growth factor receptor
  • 0 views
  • 10 Dec, 2021
  • 1 location
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2

  • 0 views
  • 11 May, 2022
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

understand the demographic and clinico-pathological profile of the patients, diagnostic practices for human epidermal growth factor receptor 2 (HER2) status, current treatment landscape and sequencing of

  • 0 views
  • 15 Jun, 2022
  • 13 locations